Seeking Alpha
30 Sept 2026, 10:31 UTC · 10h ago
Verdict
Source says Buy. We score ZTS −0.20 across three claims.
Score contradicts the headline.
Buy
Rating stated in the headline
−0.20slightly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Patent expiries for Apoquel and Simparica will occur in 2030 and 2032.
Priced inanalysis of long-term patent risks
So whatThese dates create a multi-year revenue cliff that will likely depress the P/E multiple before 2030.
More negative than 94% of claims this week
Zoetis has a pipeline of 12 candidates to offset future revenue losses.
Continue reading
5 related stories
More negative than 61% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Priced inanalysis of company pipeline
So whatA 50% success rate among these candidates is required to neutralize the 2030/2032 patent cliffs.
More positive than 80% of claims this week
The stock has declined 71% from its 2021 peak to 2017 valuation levels.
Priced inhistorical price analysis
So whatReturning to 2017 levels suggests a significant contraction in the valuation multiple compared to the 2021 peak.
More positive than 55% of claims this week
Which stocks this story touches
More negative than 61% of ticker scores this week
The company faces significant stock price decline, eroded pricing power, and future patent expiries, though it maintains strong margins and a robust pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2h ago
−0.7%
Price agrees with the score
$69.84 vs $70.30 close before publication (Sep 29) · not market-adjusted
ZTS chart →
